WallStreetZenWallStreetZen

NASDAQ: CVKD
Cadrenal Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CVKD

Based on 2 analysts offering 12 month price targets for Cadrenal Therapeutics Inc.
Min Forecast
$3.00+545.16%
Avg Forecast
$3.50+652.69%
Max Forecast
$4.00+760.22%

Should I buy or sell CVKD stock?

Based on 2 analysts offering ratings for Cadrenal Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CVKD stock forecasts and price targets.

CVKD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-14
lockedlocked$00.00+00.00%2023-12-18

1 of 1

Forecast return on equity

Is CVKD forecast to generate an efficient return?

Forecast return on assets

Is CVKD forecast to generate an efficient return on assets?

CVKD revenue forecast

What is CVKD's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$6.3M
Avg 2 year Forecast
$53.8M
Avg 3 year Forecast
$76.4M

CVKD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CVKD$0.47$3.50+652.69%Buy
KZIA$0.28N/AN/A
TENX$3.79$30.00+691.56%Strong Buy
PULM$2.03N/AN/A
TRVN$0.41$9.00+2,100.49%Buy
View Top Biotech Stocks

Cadrenal Therapeutics Stock Forecast FAQ

Is Cadrenal Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CVKD) stock is to Buy CVKD stock.

Out of 2 analysts, 0 (0%) are recommending CVKD as a Strong Buy, 2 (100%) are recommending CVKD as a Buy, 0 (0%) are recommending CVKD as a Hold, 0 (0%) are recommending CVKD as a Sell, and 0 (0%) are recommending CVKD as a Strong Sell.

If you're new to stock investing, here's how to buy Cadrenal Therapeutics stock.

What is CVKD's revenue growth forecast for 2027-2029?

(NASDAQ: CVKD) Cadrenal Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.73%.

Cadrenal Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CVKD's revenue for 2027 to be $100,853,355, with the lowest CVKD revenue forecast at $100,853,355, and the highest CVKD revenue forecast at $100,853,355. On average, 2 Wall Street analysts forecast CVKD's revenue for 2028 to be $860,615,293, with the lowest CVKD revenue forecast at $268,942,279, and the highest CVKD revenue forecast at $1,452,288,308.

In 2029, CVKD is forecast to generate $1,223,687,370 in revenue, with the lowest revenue forecast at $268,942,279 and the highest revenue forecast at $2,178,432,462.

What is CVKD's forecast return on assets (ROA) for 2027-2027?

(NASDAQ: CVKD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CVKD's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CVKD price target, the average CVKD price target is $3.50, with the highest CVKD stock price forecast at $4.00 and the lowest CVKD stock price forecast at $3.00.

On average, Wall Street analysts predict that Cadrenal Therapeutics's share price could reach $3.50 by Mar 14, 2025. The average Cadrenal Therapeutics stock price prediction forecasts a potential upside of 652.69% from the current CVKD share price of $0.47.

What is CVKD's forecast return on equity (ROE) for 2027-2027?

(NASDAQ: CVKD) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.